Vectus Biosystems (ASX:VBS) Cash-to-Debt : No Debt ⁽¹⁾ (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Vectus Biosystems Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Vectus Biosystems's cash to debt ratio for the quarter that ended in Dec. 2023 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Vectus Biosystems could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Vectus Biosystems's Cash-to-Debt or its related term are showing as below:

ASX:VBS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01 Med: 0.91 Max: No Debt
Current: 28.84

During the past 8 years, Vectus Biosystems's highest Cash to Debt Ratio was No Debt. The lowest was 0.01. And the median was 0.91.

ASX:VBS's Cash-to-Debt is ranked better than
67.97% of 1505 companies
in the Biotechnology industry
Industry Median: 6.48 vs ASX:VBS: 28.84

Vectus Biosystems Cash-to-Debt Historical Data

The historical data trend for Vectus Biosystems's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Vectus Biosystems Cash-to-Debt Chart

Vectus Biosystems Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Cash-to-Debt

Get a 7-Day Free Trial

0.02

0.38

0.75

0.21

42.16

Vectus Biosystems Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial											0.48	0.21	No Debt	42.16	No Debt

Competitive Comparison of Vectus Biosystems's Cash-to-Debt

For the Biotechnology subindustry, Vectus Biosystems's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vectus Biosystems's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vectus Biosystems's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Vectus Biosystems's Cash-to-Debt falls into.

Vectus Biosystems Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Vectus Biosystems's Cash to Debt Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	2.951	/	(0.043	+	0.027)
	=	42.16

Vectus Biosystems's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Vectus Biosystems had no debt ⁽¹⁾.

Vectus Biosystems (ASX:VBS) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Vectus Biosystems Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Vectus Biosystems's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Vectus Biosystems Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vectus Biosystems Ltd (ASX:VBS) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

3-11 Primrose Avenue, Rosebery, Sydney, NSW, AUS, 2018

Website

https://www.vectusbiosystems.com.au

Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company is in the process of developing a treatment for fibrosis and high blood pressure, which includes heart, kidney, and liver diseases. The company has also developed a technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories.

Vectus Biosystems Headlines

No Headlines

Vectus Biosystems (ASX:VBS) Cash-to-Debt : No Debt (1) (As of Dec. 2023)